(Total Views: 791)
Posted On: 09/03/2018 9:20:52 PM
Post# of 51
Senseonics and Beta Bionics Partner on Development of the Bionic Pancreas System
June 07, 2018
Long-term, implantable continuous glucose sensor to be integrated with bionic pancreas system
GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, and Beta Bionics, a medical technology company leveraging machine learning artificial intelligence to develop and commercialize the world’s first autonomous bionic pancreas, today announced that they have entered into a development agreement to integrate glucose data from the Eversense® Continuous Glucose Monitoring (CGM) system into the iLet Bionic Pancreas system.
The Eversense CGM system is a long-term, implantable continuous glucose monitoring system that continually measures interstitial fluid glucose levels and wirelessly sends the readings to a smartphone application. The iLet Bionic Pancreas system is a dual-chamber, autonomous, infusion pump that mimics a biological pancreas by automatically and autonomously adapting insulin and glucagon dosing to meet the individual needs of a person with diabetes.
“We are very excited to partner with Beta Bionics to integrate our long-term glucose sensor with the bionic pancreas system,” said Tim Goodnow, President and CEO of Senseonics. “The combination of these two technologies could create a unique option for increased simplicity, convenience and confidence in diabetes management. We are pleased to be working with the Beta Bionics team as they advance a real breakthrough for people with diabetes.”
“Senseonics has generated impressive clinical data demonstrating the remarkable accuracy of their Eversense CGM system and providing a categorically different CGM alternative for people with diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We believe that only highly accurate, reliable and safe sensors are suitable for driving automated insulin delivery systems. Based on clinical data from multiple clinical studies, the Eversense CGM system appears to meet these high standards. We are excited to partner with Senseonics to help make the iLet Bionic Pancreas system a platform of choice for people with diabetes – one that will ultimately allow people to choose between multiple CGMs, to choose between multiple insulin types, and to choose glucagon.”
Under this development agreement, Beta Bionics will work with Senseonics to integrate the Eversense CGM system with the iLet, so that real-time Eversense data may serve as one CGM option to drive the fully autonomous iLet Bionic Pancreas system.
June 07, 2018
Long-term, implantable continuous glucose sensor to be integrated with bionic pancreas system
GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, and Beta Bionics, a medical technology company leveraging machine learning artificial intelligence to develop and commercialize the world’s first autonomous bionic pancreas, today announced that they have entered into a development agreement to integrate glucose data from the Eversense® Continuous Glucose Monitoring (CGM) system into the iLet Bionic Pancreas system.
The Eversense CGM system is a long-term, implantable continuous glucose monitoring system that continually measures interstitial fluid glucose levels and wirelessly sends the readings to a smartphone application. The iLet Bionic Pancreas system is a dual-chamber, autonomous, infusion pump that mimics a biological pancreas by automatically and autonomously adapting insulin and glucagon dosing to meet the individual needs of a person with diabetes.
“We are very excited to partner with Beta Bionics to integrate our long-term glucose sensor with the bionic pancreas system,” said Tim Goodnow, President and CEO of Senseonics. “The combination of these two technologies could create a unique option for increased simplicity, convenience and confidence in diabetes management. We are pleased to be working with the Beta Bionics team as they advance a real breakthrough for people with diabetes.”
“Senseonics has generated impressive clinical data demonstrating the remarkable accuracy of their Eversense CGM system and providing a categorically different CGM alternative for people with diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We believe that only highly accurate, reliable and safe sensors are suitable for driving automated insulin delivery systems. Based on clinical data from multiple clinical studies, the Eversense CGM system appears to meet these high standards. We are excited to partner with Senseonics to help make the iLet Bionic Pancreas system a platform of choice for people with diabetes – one that will ultimately allow people to choose between multiple CGMs, to choose between multiple insulin types, and to choose glucagon.”
Under this development agreement, Beta Bionics will work with Senseonics to integrate the Eversense CGM system with the iLet, so that real-time Eversense data may serve as one CGM option to drive the fully autonomous iLet Bionic Pancreas system.
(0)
(0)
